Drug Trial Radar · NCT06740474
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 31, 2025
Primary completion
Jul 8, 2025
Study completion Jul 8, 2025
Sponsor
- Lead sponsor
- Assembly BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to assess safety, tolerability, and pharmacokinetics of single ascending doses (SAD) and multiple-ascending doses (MAD) of ABI-6250 in healthy participants. Effect of food will also be evaluated in Part A.
Conditions
- Hepatitis Delta Virus
- Hepatitis D
Interventions
ABI-6250Drug
Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
PlaceboDrug
Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with AEs, premature treatment discontinuation due to AEs and abnormal laboratory resultsTime frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Area Under the Plasma Concentration Time Curve (AUC) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Maximum Observed Plasma Concentration (Cmax) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Time to Cmax (Tmax) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Apparent Terminal Elimination Half Life (t 1/2) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Apparent Systemic Clearance (CL/F) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Apparent Volume of Distribution (Vz/F) of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
- Dose normalized AUCs and Cmax of ABI-6250Time frame: From enrollment to 10 days after the last dose, at pre-specified timepoints
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.